117661-72-0

Basic information

• Product Name: 3,4-Methylenedioxy-6-methylbenzyl chloride
• Synonyms: 3,4-Methylenedioxy-6-methylbenzyl chloride;5-CHLOROMETHYL-6-METHYL BENZO(1,3) DIOXIDE;1,3-Benzodioxole,5-(chloroMethyl)-6-Methyl-;5-(chloroMethyl)-6-Methylbenzo[d][1,3]dioxole;5-(Chloromethyl)-6-methyl-1,3-benzodioxole
• CAS NO: 117661-72-0
• Molecular Formula: C₉H₉ClO₂
• Molecular Weight: 184.61956
• Mol File: 117661-72-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 280.7±19.0℃ (760 Torr)
• Flash Point: 122.4±16.7℃
• Appearance: /
• Density: 1.276±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,4-Methylenedioxy-6-methylbenzyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Methylenedioxy-6-methylbenzyl chloride(117661-72-0)
• EPA Substance Registry System: 3,4-Methylenedioxy-6-methylbenzyl chloride(117661-72-0)

Safety Data

• Hazardous Substances Data: 117661-72-0(Hazardous Substances Data)

Usage

General Description

3,4-Methylenedioxy-6-methylbenzyl chloride is an organic compound which belongs to the class of organic compounds known as methylenedioxybenzenes. These are aromatic compounds containing a 1,3-dioxole moiety that carries a benzene ring. Benzyl Chloride, the functional group in this compound, is a molecule wherein a chlorine atom is substituted for a hydrogen atom at the methylene (-CH2-) group of the toluene. The unique properties and reactivity of the methylenedioxybenzenes and benzyl chloride moiety makes it useful in a variety of chemical reactions and synthesis. However, like most chemicals, it needs to be handled with precautions due to its potentially harmful effects.

Upstream product

• 7145-99-5 5-methyl-1,3-benzodioxole 
• 107-30-2 chloromethyl methyl ether 
• 50-00-0 formaldehyd 
• 60-29-7 diethyl ether 
• 75-09-2 dichloromethane 

Downstream Products

• 184036-34-8 sitaxentan 

Relevant articles and documents

Methods and compositions for treatment of sleep apnea

Provided herein are methods of treatment of sleep apnea by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.

Formulations of sitaxsentan sodium

Provided herein are stable lyophilized and oral formulations of sitaxsentan sodium. In certain embodiments the lyophilized formulations provided herein have improved stability upon reconstitution. Also provided are methods of making and using the formulations.

CRYSTALLINE N-(4-CHLORO-3-METHYL-5-ISOXAZOLYL)-2-[2-METHYL-4,5-(METHYLENEDIOXY)PHENYLACETYL]-THIOPHENE-3-SULFONAMIDE

Provided herein are polymorphs of N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide and pharmaceutical compositions thereof. Also provided are methods of treatment of endothelin-mediated disorders by administering a polymorph N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5-(methylenedioxy)phenylacetyl]thiophene-3-sulfonamide or pharmaceutical compositions thereof.